Debjit Chattopadhyay Analyst PerformanceSenior Managing Director at GuggenheimDebjit Chattopadhyay is a stock analyst at Guggenheim focused in the medical sector, covering 50 publicly traded companies. Over the past year, Debjit Chattopadhyay has issued 38 stock ratings, including strong buy, buy, and hold recommendations. While full access to Debjit Chattopadhyay's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Debjit Chattopadhyay's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings355 Last 11 YearsBuy Recommendations90.08% 318 Buy RatingsCompanies Covered50 Unique Companies Ratings Distribution353RatingsDistribution of strong buy, buy, hold, and sell ratings by Debjit Chattopadhyay.RatingPercentageCount Strong Buy0.6%2 ratings Buy89.5%316 ratings Hold9.9%35 ratings Sell0.0%0 ratingsOut of 353 total stock ratings issued by Debjit Chattopadhyay at Guggenheim, the majority (89.5%) have been Buy recommendations, followed by 9.9% Hold and 0.6% Strong Buy.Best & Worst CallsBest Call0000.0%MAZEFeb 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%PTCTMar 2015Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ98.0% of companies on NASDAQ49 companiesOTCMKTS2.0% of companies on OTCMKTS1 companyDebjit Chattopadhyay, an analyst at Guggenheim, currently covers 50 companies listed on NASDAQ and OTCMKTS, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical48 companies96.0%Miscellaneous1 company2.0%Manufacturing1 company2.0%Debjit Chattopadhyay of Guggenheim specializes in stock coverage within the Medical sector, with additional focus on and Manufacturing companies.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE34 companies68.0%MED - DRUGS8 companies16.0%BIOTECHNOLOGY2 companies4.0%PHARMACEUTICAL PREPARATIONS2 companies4.0%Miscellaneous1 company2.0%MED PRODUCTS1 company2.0%BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC1 company2.0%DIAGNOSTIC SUBSTANCES1 company2.0% Debjit Chattopadhyay's Ratings History at Guggenheim Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsIRDOpus Genetics6/4/2026Initiated Coverage$4.20$16.00Buy$0.0000.00% ROIIRDOpus Genetics6/4/2026Upgrade$4.64$16.00Strong-Buy$0.0000.00% ROIRAREUltragenyx Pharmaceutical5/8/2026Lower Price Target$26.13$43.00Buy$0.0000.00% ROIMSLESatellos Bioscience4/28/2026Initiated Coverage$7.16$23.00Buy$0.0000.00% ROICNTACentessa Pharmaceuticals4/2/2026Downgrade$39.71Hold$0.0000.00% ROISLDBSolid Biosciences3/20/2026Initiated Coverage$7.12$26.00Buy$0.0000.00% ROIMAZEMaze Therapeutics3/4/2026Boost Price Target$44.18$58.00Buy$0.0000.00% ROIKRYSKrystal Biotech2/25/2026Boost Price Target$270.43$284.00Buy$0.0000.00% ROIBMRNBioMarin Pharmaceutical2/25/2026Lower Price Target$61.51$86.00Buy$0.0000.00% ROINAMSNewAmsterdam Pharma2/19/2026Boost Price Target$35.76$45.00Buy$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. PEPGPepGen2/18/2026Boost Price Target$6.79$7.00Buy$0.0000.00% ROITRDAEntrada Therapeutics2/11/2026Upgrade$10.80Strong-Buy$0.0000.00% ROITRDAEntrada Therapeutics2/10/2026Initiated Coverage$10.82$20.00Buy$0.0000.00% ROIRAREUltragenyx Pharmaceutical1/5/2026Lower Price Target$23.60$52.00Buy$0.0000.00% ROIMAZEMaze Therapeutics12/19/2025Reiterated Rating$40.62$46.00Buy$0.0000.00% ROIRZLTRezolute12/12/2025Lower Price Target$1.40$6.00Buy$0.0000.00% ROIPHVSPharvaris12/4/2025Boost Price Target$29.36$39.00Buy$0.0000.00% ROICNTACentessa Pharmaceuticals11/18/2025Boost Price Target$28.09$43.00Buy$0.0000.00% ROISRPTSarepta Therapeutics11/5/2025Lower Price Target$18.35$19.00Buy$0.0000.00% ROINTLAIntellia Therapeutics10/27/2025Downgrade$14.39Neutral$0.0000.00% ROIKRYSKrystal Biotech10/17/2025Set Price Target$188.33$224.00Buy$0.0000.00% ROILXEOLexeo Therapeutics10/15/2025Initiated Coverage$8.50$30.00Buy$0.0000.00% ROILXEOLexeo Therapeutics10/15/2025Initiated Coverage$8.77$30.00Buy$0.0000.00% ROICNTACentessa Pharmaceuticals10/6/2025Reiterated Rating$23.23$28.00Buy$0.0000.00% ROIQUREuniQure9/25/2025Boost Price Target$47.50$95.00Buy$0.0000.00% ROIPEPGPepGen9/24/2025Reiterated Rating$1.95$6.00Buy$0.0000.00% ROIIONSIonis Pharmaceuticals9/23/2025Boost Price Target$61.36$92.00Buy$0.0000.00% ROIRZLTRezolute9/22/2025Reiterated Rating$7.70$15.00Buy$0.0000.00% ROISRPTSarepta Therapeutics9/15/2025Reiterated Rating$17.39$22.00Buy$0.0000.00% ROIMAZEMaze Therapeutics9/15/2025Boost Price Target$23.30$34.00Buy$0.0000.00% ROIPEPGPepGen9/9/2025Initiated Coverage$1.49$6.00Buy$0.0000.00% ROISLNOSoleno Therapeutics8/27/2025Reiterated Rating$69.77$106.00Buy$0.0000.00% ROINTLAIntellia Therapeutics8/13/2025Reiterated Rating$10.86$14.00Buy$0.0000.00% ROISLNOSoleno Therapeutics8/7/2025Boost Price Target$80.99$106.00Buy$0.0000.00% ROIBMRNBioMarin Pharmaceutical8/6/2025Boost Price Target$61.27$106.00Buy$0.0000.00% ROIVRTXVertex Pharmaceuticals8/6/2025Lower Price Target$387.47$546.00Buy$0.0000.00% ROIRAREUltragenyx Pharmaceutical6/20/2025Reiterated Rating$36.88$64.00Buy$0.0000.00% ROIDYNDyne Therapeutics6/18/2025Reiterated Rating$11.00$50.00Buy$0.0000.00% ROINTLAIntellia Therapeutics5/12/2025Lower Price Target$8.71$45.00Buy$00.0000.00% ROIQUREuniQure5/12/2025Reiterated Rating$12.76$28.00Buy$00.0000.00% ROITrump's gold order: the announcement they won't put on the front page (Ad)On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.Request the free guide in 30 seconds and get positioned nowSLNOSoleno Therapeutics5/8/2025Boost Price Target$78.63$97.00Buy$00.0000.00% ROIKRYSKrystal Biotech5/7/2025Lower Price Target$136.13$189.00Buy$000.0000.00% ROIBEAMBeam Therapeutics5/7/2025Lower Price Target$15.70$55.00Buy$00.0000.00% ROISRPTSarepta Therapeutics5/7/2025Lower Price Target$37.57$98.00Buy$00.0000.00% ROIIONSIonis Pharmaceuticals5/1/2025Lower Price Target$31.98$64.00Buy$00.0000.00% ROIIONSIonis Pharmaceuticals4/3/2025Reiterated Rating$27.98Buy$00.0000.00% ROISLNOSoleno Therapeutics3/28/2025Reiterated Rating$67.39$81.00Buy$00.0000.00% ROICNTACentessa Pharmaceuticals3/26/2025Reiterated Rating$14.83$28.00Buy$00.0000.00% ROIBEAMBeam Therapeutics2/27/2025Reiterated Rating$29.04$78.00Buy$00.0000.00% ROIMAZEMaze Therapeutics2/25/2025Initiated Coverage$11.33$19.00Buy$00.0000.00% ROICNTACentessa Pharmaceuticals2/10/2025Reiterated Rating$19.03Buy$00.0000.00% ROIDYNDyne Therapeutics1/24/2025Reiterated Rating$13.50Buy$00.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenUBS GroupCitigroupBarclaysWells Fargo & CompanyMorgan StanleyRoyal Bank Of CanadaJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerStifel NicolausRaymond James Financial Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
